Plus Therapeutics Withdraws $PSTV Stock Registration, Delays Share Offering

Plus Therapeutics has submitted a request to withdraw its Registration Statement on Form S-3 (File No. 333-286393) that was initially filed on April 4, 2025, and amended on April 23, 2025.

Rhea-AI Filing Summary

Plus Therapeutics has submitted a request to withdraw its Registration Statement on Form S-3 (File No. 333-286393) that was initially filed on April 4, 2025, and amended on April 23, 2025.

Key points of the withdrawal request:

• The company has decided not to proceed with the registration of the contemplated resale of securities
• Confirms that no securities were sold under this Registration Statement
• Requests that all fees paid to the SEC be credited to the company's account for future registration statement filings under Rule 457(p)
• The withdrawal request is made pursuant to Rule 477(a) under the Securities Act of 1933

This withdrawal indicates a change in the company's capital raising or securities registration strategy, though specific reasons for the withdrawal were not disclosed.

Positive

• None.

Negative

• Company withdraws Form S-3 registration statement for resale of securities, indicating a change in capital raising strategy or market conditions

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did PSTV withdraw its S-3 registration statement in June 2025?

PSTV withdrew its S-3 registration statement (File No. 333-286393) because the company determined not to proceed with the contemplated resale of securities at this time. The company confirmed that no securities were sold pursuant to the Registration Statement.

When was PSTV's S-3 registration statement originally filed?

PSTV's S-3 registration statement was initially filed with the SEC on April 4, 2025, and was subsequently amended on April 23, 2025.

What happens to the filing fees PSTV paid for the withdrawn S-3 registration?

According to the withdrawal request, PSTV requested that all fees paid to the SEC in connection with the filing be credited to the company's account under Rule 457(p), to be offset against filing fees for any future registration statements the company may file.

Who is the current CEO of PSTV as of the June 2025 filing?

Marc H. Hedrick, MD serves as the President & Chief Executive Officer of PSTV, as evidenced by his signature on the withdrawal request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2025 - 04:15 PM Learn about SEC filing dates

PLUS THERAPEUTICS, INC.

2710 Reed Road, Suite 160

Houston, Texas 77051

June 23, 2025

VIA EDGAR

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

 

Re: Plus Therapeutics, Inc.

Registration Statement on Form S-3 (File No. 333-286393)

Request for Withdrawal of Registration Statement

Ladies and Gentlemen:

Reference is made to the Registration Statement on Form S-3 (File No. 333-286393) initially filed with the Securities and Exchange Commission (the “Commission”) by Plus Therapeutics, Inc. (the “Company”) on April 4, 2025, as amended on April 23, 2025, together with all exhibits thereto (the “Registration Statement”). Pursuant to Rule 477(a) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), the Company hereby respectfully requests that the Commission consent to the withdrawal of the Registration Statement, effective immediately.

The Company has determined not to register, at this time, the contemplated resale of securities to which the Registration Statement relates. The Company confirms that no securities have been sold pursuant to the Registration Statement.

The Company requests in accordance with Rule 457(p) under the Securities Act that all fees paid to the Commission in connection with the filing of the Registration Statement be credited to the Company’s account to be offset against the filing fee for any future registration statement the Company may file with the Commission.

Upon the granting of the Commission’s consent, please send copies of the order withdrawing the Registration Statement to the undersigned, and to the Company’s legal counsel, Sullivan & Worcester LLP, Attn: Aaron M. Schleicher.

Thank you for your attention to this matter. If you have any questions or require additional information, please do not hesitate to contact Aaron M. Schleicher of Sullivan & Worcester LLP at (603) 425-3210.

 

Sincerely,

/s/ Marc H. Hedrick, M.D.

Marc H. Hedrick, MD

President & Chief Executive Officer